Oral Contraceptives: The Extended Cycle Regimen

Extended use of combination monophasic oral contraceptives (OCs) used to treat women with menstrual disorders, such as endometriosis and dysmenorrhea, has been proven to be safe, effective, and acceptable to women. Even women without a medical indication for menstrual suppression may find that extending OC therapy may yield an improvement in their quality of life by diminishing menstrual symptoms associated with hormone withdrawal during the placebo interval. Most physicians and many women are aware of how to extend OC therapy, and commonly manipulate their cycles to avoid unwanted menstruation at inopportune times, such as during a honeymoon, vacation, or exams.

Related Content

Advertisement

---

FDA Approves First Nonprescription Oral Contraceptive

July 13th 2023

Article

Opill will be available in stores and online in the first quarter of 2024.

---

FDA Schedules Advisory Committee Meeting for OTC Contraceptive

March 29th 2023

Article

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

---

FDA Approves Second Indication for Brexafemme

December 2nd 2022

Article

Brexafemme is a non-azole oral antifungal now approved to both treat and prevent recurrent yeast infections in women.

---

FDA Approves Liletta IUD to Prevent Pregnancy for 8 Years

November 14th 2022

Article

The approval extends the use of Liletta for an additional two years. It is the only hormonal IUD approved for continuous use up to eight years.

---

Real-world Data Show Gardasil Protects Against Cervical, Non-Cervical Diseases

November 7th 2022

Article

The greatest reductions were seen in girls who were vaccinated when they were adolescents, with up to 73% reduction in cervical pre-cancerous lesions.

---

FDA Postpones Advisory Committee Meeting for OTC Birth Control

October 27th 2022

Article

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

Related Content

Advertisement

---

FDA Approves First Nonprescription Oral Contraceptive

July 13th 2023

Article

Opill will be available in stores and online in the first quarter of 2024.

---

FDA Schedules Advisory Committee Meeting for OTC Contraceptive

March 29th 2023

Article

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

---

FDA Approves Second Indication for Brexafemme

December 2nd 2022

Article

Brexafemme is a non-azole oral antifungal now approved to both treat and prevent recurrent yeast infections in women.

---

FDA Approves Liletta IUD to Prevent Pregnancy for 8 Years

November 14th 2022

Article

The approval extends the use of Liletta for an additional two years. It is the only hormonal IUD approved for continuous use up to eight years.

---

Real-world Data Show Gardasil Protects Against Cervical, Non-Cervical Diseases

November 7th 2022

Article

The greatest reductions were seen in girls who were vaccinated when they were adolescents, with up to 73% reduction in cervical pre-cancerous lesions.

---

FDA Postpones Advisory Committee Meeting for OTC Birth Control

October 27th 2022

Article

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.